Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multi-center, Open-label, Study to Investigate the Safety, Tolerability and Pharmacokinetic of SLC-0111 in Subjects With Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase I, Multi-center, Open-label, Study to Investigate the Safety, Tolerability and Pharmacokinetic of SLC-0111 in Subjects With Advanced Solid Tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SLC 0111 (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Phaeochromocytoma; Renal cell carcinoma; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors SignalChem Lifesciences; Welichem Biotech

    • Most Recent Events

    • 28 Apr 2020 Results presented at the 111th Annual Meeting of the American Association for Cancer Research - I
    • 13 May 2016 Status changed from recruiting to completed.
    • 08 Dec 2015 Planned number of patients changed from 34 to 24 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top